SCHEMBL710223

SCHEMBL710223

CCS(=O)(=O)c1ccc(Br)c(C)c1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
LMNA P02545 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
GAA P10253 1/20 0.44
PSIP1 O75475 2/20 0.43
HTT P42858 1/20 0.42
ABL1 P00519 1/20 0.41
RIN1 Q13671 1/20 0.41
IDO1 P14902 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
CCR2 P41597 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1368328 0.84 GAA (0.44) ALDH1A1LMNAMEN1KMT2AGAA
SCHEMBL5524384 0.81 ALDH1A1 (0.50) ALDH1A1LMNAMEN1KMT2AL3MBTL1
SCHEMBL27229115 0.80 GAA (0.53) ALDH1A1LMNAGAAPSIP1HTT
SCHEMBL851152 0.79 CA2 (0.55) ALDH1A1LMNAMEN1KMT2AL3MBTL1
SCHEMBL29421567 0.79 LMNA (0.49) ALDH1A1LMNAMEN1KMT2AL3MBTL1
SCHEMBL394533 0.79 LMNA (0.49) ALDH1A1LMNAMEN1KMT2AL3MBTL1
SCHEMBL708295 0.78 GAA (0.42) ALDH1A1LMNAMEN1KMT2AGAA
SCHEMBL2112292 0.78 GAA (0.42) ALDH1A1GAAPSIP1IDO1PTGDR2
SCHEMBL29678127 0.78 GAA (0.42) ALDH1A1LMNAMEN1KMT2AGAA
SCHEMBL30602398 0.78 GAA (0.42) ALDH1A1GAAPSIP1IDO1PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611091-B1 Substituted phenylalkanoic acid derivatives and their use for respiratory disease treatment ASTRAZENECA AB (SE) 2014-10-29 EP disclosed
US-20140256756-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2014-09-11 US disclosed
US-20140256756-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2014-09-11 US disclosed
US-20140256756-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2014-09-11 US disclosed
US-8394986-B2 Phenoxiacetic acid derivatives ASTRAZENECA AB (GB) 2013-03-12 US disclosed
US-8158820-B2 Compounds ASTRAZENECA AB (SE) 2012-04-17 US disclosed
US-8124629-B2 Naphthylacetic acids HOFFMANN-LA ROCHE INC. (US) 2012-02-28 US disclosed
US-8124629-B2 Naphthylacetic acids HOFFMANN-LA ROCHE INC. (US) 2012-02-28 US disclosed
US-8124629-B2 Naphthylacetic acids HOFFMANN-LA ROCHE INC. (US) 2012-02-28 US disclosed
US-20110281898-A1 PHENOXIACETIC ACID DERIVATIVES ASTRAZENECA AB 2011-11-17 US disclosed
CN-100575330-C Novel compounds ASTRAZENECA AB 2009-12-30 CN disclosed
EP-1660431-B1 PHENOXYACETIC ACID DERIVATIVES ASTRAZENECA AB (SE) 2009-04-01 EP disclosed
US-20060293352-A1 Phenoxiacetic acid derivatives ASTRAZENECA AB (SE) 2006-12-28 US disclosed
US-20060264435-A1 Novel compounds ASTRAZENECA AB (SE) 2006-11-23 US disclosed
CN-1845894-A phenoxyacetic acid derivatives ASTRAZENECA AB (SE) 2006-10-11 CN disclosed
CN-1791572-A Novel compounds ASTRAZENECA AB (SE) 2006-06-21 CN disclosed
EP-1660431-A2 PHENOXYACETIC ACID DERIVATIVES Astrazeneca AB (SE) 2006-05-31 EP disclosed
EP-1611091-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2006-01-04 EP disclosed
WO-2005018529-A2 PHENOXIACETIC ACID DERIVATIVES ASTRAZENECA AB (SE) 2005-03-03 WO disclosed
WO-2004089885-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256756-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS GPR119, GPR139, GLP1R ALDH1A1 2778/4885LMNA 2377/4885MEN1 3712/4885
US-20060293352-A1 Phenoxiacetic acid derivatives HRH2, HRH1, HCAR2 ALDH1A1 616/4885LMNA 2569/4885MEN1 3996/4885
US-20060264435-A1 Novel compounds ADRA2C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR2 ALDH1A1 284/4885LMNA 2362/4885MEN1 3390/4885
US-20110281898-A1 PHENOXIACETIC ACID DERIVATIVES HIF1A, HPD, HIF1AN ALDH1A1 550/4885LMNA 889/4885MEN1 3563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.